1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015’, provides an overview of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 6
Therapeutics Development 7
Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 7
Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 8
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 9
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 13
Human Stem Cells Institute 13
Juventas Therapeutics, Inc. 14
Lacer, S.A. 15
Nuo Therapeutics, Inc. 16
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ALD-201 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Biglycan Therapy for Cardiovascular Diseases - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Cryocell - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
JVS-100 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
LA-419 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 34
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables

Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 7
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2015 13
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H1 2015 14
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H1 2015 15
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H1 2015 34
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2015 37

List of Figures

Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 7
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Top 10 Targets, H1 2015 18
Number of Products by Stage and Top 10 Targets, H1 2015 19
Number of Products by Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
Number of Products by Top 10 Molecule Types, H1 2015 24
Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.